Breen Michael Martin
Breen Michael Martin's purchase track record
Breen Michael Martin has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/3/2023 | PROP | $100K | +108.9% | +459.1% | +3.6% |
| 4/11/2023 | GTBP | $25K | -48.1% | -52.7% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PROP Listed Among 10 Energy Stocks Moving Pre-Market. Prairie Operating Co. stock was highlighted in a Benzinga report listing ten energy names with notable pre-market activity. The stock currently trades well below its 52-week high of $2.55, with an average analyst target of $2.00. This news provides context for recent price movements, though the specific reasons for the pre-market volatility are not detailed in the provided data.
Transaction History
| GTBP | ▲ Buy | Grant | 200,000 | $57K | 8/11/2023 | View on chart |
| PROP | ▲ Buy | Open Market | 916,112 | $100K | 5/3/2023 | View on chart |
| PROP | ▲ Buy | Grant | 218,571 | $38K | 5/3/2023 | View on chart |
| GTBP | ▲ Buy | Open Market | 50,000 | $25K | 4/11/2023 | View on chart |
| GTBP | ▲ Buy | Grant | 278,058 | $0 | 7/15/2022 | View on chart |
| GTBP | ▼ Sell | Other | 40,243 | $137K | 2/25/2021 | View on chart |
| GTBP | ▼ Sell | Other | 9,859 | $34K | 2/25/2021 | View on chart |
| GTBP | ▲ Buy | Grant | 278,058 | $0 | 2/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
GT Biopharma Files Prospectus for Up to 13.5M Shares
GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.
GT Biopharma Files Prospectus for Up to 13.5M Shares. GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.